rs1010 — VAMP8 VAMP8 3'UTR Variant

Common 3'UTR variant in VAMP8 associated with modestly elevated myocardial infarction and noncardioembolic stroke risk

See your personal result for VAMP8

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

VAMP8 3'UTR Variant — A Platelet Degranulation Regulator Linked to Arterial Thrombosis

When a platelet is activated at a site of vascular injury, it releases a cascade of pro-aggregatory molecules from its internal storage granules — a process called degranulation11 degranulation
the release of platelet granule contents (ADP, serotonin, thromboxane A2, fibrinogen) that amplifies the coagulation response and recruits additional platelets to the growing thrombus. The molecular machinery that executes this release depends on a family of vesicle-docking proteins called SNAREs. VAMP8 (vesicle-associated membrane protein 8, also known as endobrevin) is the key v-SNARE mediating fusion of dense granules and alpha-granules with the platelet plasma membrane. Without sufficient VAMP8, granule release is impaired; with excess VAMP8, platelets become hyperreactive. The rs1010 variant sits in the 3' untranslated region of VAMP8 mRNA.

The Mechanism

The 3'UTR of a gene's mRNA transcript is the regulatory tail that controls message stability, localization, and translation efficiency — particularly through binding of small RNA molecules called microRNAs22 microRNAs
20–23 nucleotide RNA molecules that bind complementary sequences in the 3'UTR of target mRNAs and suppress translation or trigger degradation. Research by Kondkar et al. identified microRNA-96 (miR-96) as a regulator of VAMP8 expression: miR-96 caused dose-dependent decreases in both VAMP8 protein and mRNA in platelet-model cell lines.

Higher VAMP8 protein translates to a lower threshold for degranulation: platelets with more VAMP8 release their contents more readily when stimulated by ADP, thrombin, collagen, or other agonists. Hyperreactive platelets — those with more pronounced degranulation — are an established intermediate phenotype on the causal pathway to arterial thrombosis.

Importantly, one study (Gaussem et al. 2009) found no association between rs1010 genotype and standard in vitro platelet function assays (aggregometry, flow cytometry for activation markers), suggesting the effect may be subtle, age-dependent, or context-specific rather than universally detectable under laboratory conditions.

The Evidence

The cardiovascular association evidence comes from several independent cohorts:

Shiffman et al.33 Shiffman et al.
Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol, 2008 prospectively followed 4,522 adults aged ≥65 years and found the VAMP8 rs1010 C allele associated with incident MI at a hazard ratio of 1.2 (90% CI 1.02–1.41). This placed VAMP8 among the four SNPs with the strongest evidence for cardiovascular association in that panel.

Bare et al.44 Bare et al.
Five common gene variants identify elevated genetic risk for coronary heart disease. Genet Med, 2007 included rs1010 in a composite five-variant cardiovascular risk score applied to 9,129 ARIC Study participants. Those in the top genetic risk tier had an HR of 1.57 (95% CI 1.21–2.04, P=0.001) for incident coronary heart disease versus the low-risk group.

Luke et al.55 Luke et al.
Polymorphisms associated with noncardioembolic stroke and coronary heart disease. Cerebrovasc Dis, 2009 extended the finding to cerebrovascular events, reporting OR=1.21 (90% CI 0.99–1.49) for noncardioembolic stroke per C allele in the Vienna Stroke Registry — consistent in direction with the MI signal.

At the protein level, Kondkar et al.66 Kondkar et al.
VAMP8/endobrevin is overexpressed in hyperreactive human platelets. J Thromb Haemost, 2010 found VAMP8 mRNA 4.8-fold higher in hyperreactive versus hyporeactive platelets (P=0.0023) across 288 healthy individuals, with protein levels varying 13-fold across subjects and 2.5-fold higher in the hyperreactive group (P=0.05). rs1010 was associated with platelet reactivity in an age-dependent manner (P<0.003). The Llobet et al. 201977 Llobet et al. 2019 thrombosis study reinforced the protein-level emphasis: elevated VAMP8 protein was associated with venous thrombosis in women (OR=3.25), but the rs1010 genotype itself showed no significant association.

The overall evidence level is moderate: replicated association with MI and stroke in multiple cohorts, plausible and partially characterized molecular mechanism, but contradictory in vitro platelet data and effect sizes in the HR=1.2 range that are modest and do not reach genome-wide significance thresholds.

Practical Actions

Carriers of one or two C alleles should be aware of their modestly elevated arterial thrombotic risk.

Antiplatelet therapy (aspirin, clopidogrel, ticagrelor) targets multiple steps in the platelet activation pathway including SNARE-mediated degranulation; whether rs1010 status predicts differential antiplatelet response is not yet established.

Genotype Interpretations

What each possible genotype means for this variant.

TT Standard VAMP8 Expression Normal

Reference genotype — typical platelet degranulation capacity

In the Cardiovascular Health Study (Shiffman et al. 2008), the T/T genotype represents the non-risk reference group against which C allele carriers were compared. The hazard ratio of 1.2 per C allele for MI, and OR of ~1.21 for noncardioembolic stroke (Luke et al. 2009), are derived relative to this T/T reference.

CT One C Allele Intermediate

One copy of the C allele — modestly elevated platelet activation potential

Kondkar et al. 2010 observed the rs1010-platelet reactivity association in an age-dependent fashion.

The Gaussem et al. 2009 study found no significant in vitro platelet function differences by genotype, cautioning against over-interpreting the laboratory-to-clinical translation. The clinical HR of 1.2 is modest and represents one contributor among many to overall thrombotic risk.

CC Two C Alleles High Risk

Two copies of the C allele — highest VAMP8 expression and platelet activation potential

Kondkar et al. 2010 found VAMP8 protein levels vary 13-fold across individuals, with 2.5-fold higher levels in hyperreactive platelets.

The Llobet et al. 2019 study observed that elevated VAMP8 protein (not merely the C allele genotype) associated with venous thrombosis in women (OR=3.25).

The overall evidence is moderate: the association is replicated, the mechanism is partially characterized, but effect sizes are modest (HR ~1.2 per allele in the largest prospective study) and one controlled platelet-function study found no in vitro difference. C/C homozygosity warrants awareness and targeted monitoring rather than alarm.